Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 147-152

  Leppänen, Pia ^a   Luoma, Jukka S ^a   Hofker, Marten H ^b   Havekes, Louis M ^b   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TNO   (Netherlands)

Author keywords

Apo E; Familial dyslipoproteinemia; LRP; Oxidized LDL; Scavenger receptor

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DYSLIPOPROTEINEMIA; FAMILIAL DISEASE; HYPERLIPIDEMIA; IMMUNOCYTOCHEMISTRY; LIPOPROTEIN METABOLISM; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; AORTA; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL; ELECTROPHORESIS, AGAR GEL; FOAM CELLS; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LDL;

EID: 0344382051     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00196-2     Document Type: Article

References (29)

1. Havekes L., de Wit E., Gevers Leuven J., Klasen E., Utermann G., Weber W., Beisiegel U. Apolipoprotein E3 leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum Genet. 73:1986;157-163.
2. Van den Maagdenberg A.M.J.M., de Knijff P., Stalenhoef J., Gevers Leuven L.M., Havekes L.M., Frants R.R. Apolipoprotein E3 leiden allele results from a partial gene duplication in exon 4. Biochem Biophys Res Commun. 165:1989;851-857.
3. De Knijff P., van den Maagdenberg A.M.J.M., Stalenhoef A.F.H., Gevers Leuven J.A., Demacker P.N.M., Kuyt L.P., Frants R.R., Havekes L.M. Familial dysbetalipoproteinemia associated with apolipoprotein E3-leiden in an extended multigeneration pedigree. J Clin Invest. 88:1991;643-655.
4. Fazio S., Horie Y., Weisgraber K.H., Havekes L.M., Rall S.C. Preferential association of apolipoprotein E leiden with very low density lipoproteins of human plasma. J Lipid Res. 34:1993;447-453.
5. Van der Maagdenberg A.M.J.M., Hofker M.H., Krimpenfort P.J., de Bruijn I., van Vlijmen B., van der Boom H., Havekes L.M., Frants R.R. Transgenic mice carrying the apolipoprotein E3-leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 268:1993;10540-10545.
6. Van Vlijmen B., van den Maagdenberg A.M.J.M., Gijbels M.J.J., van der Boom H., HogenEsch H., Frants R.R., Hofker M.H., Havekes L.M. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-leiden transgenic mice. J Clin Invest. 93:1994;1403-1410.
7. Van Vlijmen B.J.M., van't Hof H.B., Mol M.J.T.M., van der Boom H., van der Zee A., Frants R.R., Hofker M.H., Havekes L.M. Modulation of very low density lipoprotein production and clearance contributes to age and gender dependent hyperlipoproteinemia in apolipoprotein E3-leiden transgenic mice. J Clin Invest. 97:1996;1184-1192.
8. Groot P.H.E., van Vlijmen B., Benson G.M., Hofker M.H., Schiffelers R., Vidgeon-Hart M., Havekes L.M. Quantitative assessment of aortic atherosclerosis in apo E3 leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol. 16:1996;926-933.
9. Nishina P.M., Verstuyft J., Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 31:1990;859-869.
10. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 92:1993;883-893.
11. Ylä-Herttuala S., Rosenfeld M.E., Parthasarathy S., Glass C.K., Sigal E., Witztum J.L., Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA. 87:1990;6959-6963.
12. Rosenfeld M.E., Palinski W., Ylä-Herttuala S., Butler S., Witztum J.L. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:1990;336-349.
13. 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen. Exp Cell Res. 190:1990;195-204.
14. 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest. 93:1994;2014-2021.
15. Fraser I., Hughes D., Gordon S. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature. 364:1993;343-346.
16. Palinski W., Ylä-Herttuala S., Rosenfeld M.E., Butler S., Socher S.A., Parthasarathy S., Curtiss L.K., Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 10:1990;325-335.
17. Plump A.S., Smith J.D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
18. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. Apo E-deficient mice are a model of lipoprotein oxidation in atherogenesis. Arterioscler Thromb. 14:1994;605-616.
19. Palinski W., Tangirala R.K., Miller E., Young S.G., Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 15:1995;1569-1576.
20. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 52:1983;223-261.
21. Rosenfeld M.E., Butler S., Ord V.A., Lipton B.A., Dyer C.A., Curtiss L.K., Palinski W., Witztum J.L. Abundant expression of apolipoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb. 13:1993;1382-1389.
22. Bellosta S., Mahley R.W., Sanan D.A., Murata J., Newland D.L., Taylor J.M., Pitas R.E. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 96:1995;2170-2179.
23. Shimano H., Ohsuga J., Shimada M., Namba Y., Gotoda T., Harada K., Katsuki M., Yazaki Y., Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest. 95:1995;469-476.
24. Linton R.F., Atkinson J.B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267:1995;1034-1037.
25. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol; modification of low-density lipoprotein that increase its atherogeneicity. New Engl J Med. 320:1989;915-924.
26. Ylä-Herttuala S., Rosenfeld M.E., Parthasarathy S., Sigal E., Särkioja T., Witztum J.L., Steinberg D. Gene expression in macrophage-rich human atherosclerotic lesions; 15-lipoxygenase and acetyl LDL receptor mRNA colocalize with oxidation specific lipidprotein adducts. J Clin Invest. 87:1991;90-99.
27. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors. Macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem. 63:1994;601-637.
28. Ylä-Herttuala S. Expression of lipoprotein receptors and related molecules in atherosclerotic lesions. Curr Opin Lipidol. 7:1996;292-297.
29. Sasahara M., Raines E.W., Chait A., Carew T.E., Steinberg D., Wahl P.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. J Clin Invest. 94:1994;155-164.